Leading kefir brand seeks to raise awareness around new gut health research, applauds study linking long-term fermented milk consumption to lower colorectal cancer risk MORTON GROVE, Ill., March 3, 2025 /PRNewswire/ -- Lifeway Foods, Inc. (Nasdaq: LWAY), a leading U.S. supplier of kefir and fermented probiotic products, announced today that Lifeway President and CEO Julie Smolyansky will appear with Katie Couric at the SXSW conference to discuss the company's history, innovations in microbiome r

Dr. Pierce Nunley completes the first U.S. PerQdisc Surgery Spine Surgeon Dr. Frank Phillips Joins SST Board of Directors SAN ANTONIO, March 3, 2025 /PRNewswire/ -- Spinal Stabilization Technologies, LLC (SST) has announced a significant milestone in its mission to revolutionize spinal care: the enrollment of the first U.S. patient in its Investigational Device Exemption (IDE) clinical trial for the PerQdisc Nucleus Replacement Device (NRD). This event marks the beginning of SST's U.S.-based tr

NEW YORK, March 3, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Walgreens Boots Alliance, Inc. ("Walgreens" or the "Company") (NASDAQ: WBA) and certain officers. The class action, filed in the United States District Court for the Northern District of Illinois, and docketed under 25-cv-01058, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Walgreens common stock between Apr

JUPITER, Fla., Feb. 26, 2025 /PRNewswire/ -- Myosin Therapeutics, Inc., a biotechnology company developing novel therapies for cancer and neurological disorders, has closed its second seed funding round, raising over $3 million to supplement significant investment from the National Institutes of Health. Myosin Therapeutics, Inc. (the "Company") is advancing its lead compound, MT-125, to treat glioblastoma, the most aggressive brain cancer with an average survival time of only 8 months. MT-125 ta

Risk reduced if treatment started within two years of diagnosis MINNEAPOLIS, March 3, 2025 /PRNewswire/ -- People with obstructive sleep apnea have an increased risk of Parkinson's disease, but if started early enough, continuous positive airway pressure (CPAP) may reduce that risk, according to a preliminary study released March 2, 2025, that will be presented at the American Academy of Neurology's 77th Annual Meeting taking place April 5–9, 2025, in San Diego and online. The study found using

Expanding Services and Footprint Into New England States PLANTATION, Fla., March 3, 2025 /PRNewswire/ -- BioMatrix Infusion Pharmacy, a leading provider in ambulatory and home infusion services, has announced the acquisition of MyLyfe Health. MyLyfe Health specializes in specialty pharmacy, home infusion, and infusion suite services for patients with chronic, lifelong medical conditions. Continue Reading This strategic acquisition strengthens BioMatrix's position in the infusion pharmacy market,

Interim Phase 1 results for APG990, a novel half-life extended OX40L antibody, exceeded trial objectives and demonstrated an approximately 60-day half-life APG279 (APG777 + APG990) Phase 1b head-to-head study vs. DUPIXENT supported by successful completion of preclinical combination toxicology studies and positive APG990 interim Phase 1 results; trial planned to initiate this year with readout expected in second half of 2026 SAN FRANCISCO, CA and BOSTON, MA, USAI March 03, 2025 I Apogee Therapeu

– Topline SAD data from healthy volunteers demonstrate safety, tolerability, and dose-proportional pharmacokinetics, supporting potentially best-in-class profile – – MAD study initiated in patients with early Alzheimer’s disease; initial tau PET imaging data expected in H2 2026 – LEXINGTON, MA, USA I March 03, 2025 I Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced positive topline data from the Company’s single asc

– CDX-622 inhibits SCF and TSLP-dependent inflammatory signatures in human skin – – Phase 1 study in healthy volunteers ongoing – HAMPTON, NJ, USA I March 03, 2025 I Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today positive preclinical data from CDX-622, a novel bispecific antibody that targets two non-redundant, complementary pathways implicated in inflammation and fibrosis—thymic stromal lymphopoietin (TSLP) and mast cell depletion via stem cell factor (SCF) starvation. The data demons

− Study met the primary endpoint, with a significantly higher proportion of clinical responders on rusfertide compared to placebo − All four key secondary endpoints were met, including EU primary endpoint and patient-reported outcomes − Rusfertide was generally well tolerated; no new safety findings were observed in the study NEWARK, CA, USA & OSAKA, Japan & CAMBRIDGE, MA, USA I March 03, 2025 I Protagonist Therapeutics, Inc. (“Protagonist”) ( NASDAQ:PTGX ) and Takeda ( TSE:4502/NYSE:TAK ) today